RORα and γ, alternative receptors for vitamin D-hydroxyderivatives, are expressed at lower levels in melanomas than in nevi and their expression decreases during melanoma progression, with lowest expression found in stage III and IV melanomas and in metastases (76). The gene discussed is RORA; the disease is melanoma.